Found: 16
Select item for more details and to access through your institution.
Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining‐targeted biopsy.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 572, doi. 10.1002/pros.24490
- By:
- Publication type:
- Article
Identification of androgen response‐related lncRNAs in prostate cancer.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 590, doi. 10.1002/pros.24494
- By:
- Publication type:
- Article
Detection of intraductal carcinoma in prostate cancer patients with small tumor volume.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 580, doi. 10.1002/pros.24492
- By:
- Publication type:
- Article
Low‐risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 498, doi. 10.1002/pros.24493
- By:
- Publication type:
- Article
Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 489, doi. 10.1002/pros.24491
- By:
- Publication type:
- Article
ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 602, doi. 10.1002/pros.24495
- By:
- Publication type:
- Article
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 613, doi. 10.1002/pros.24489
- By:
- Publication type:
- Article
Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 563, doi. 10.1002/pros.24488
- By:
- Publication type:
- Article
Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 612, doi. 10.1002/pros.24487
- By:
- Publication type:
- Article
Commentary.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 614, doi. 10.1002/pros.24486
- By:
- Publication type:
- Article
Androgen deprivation therapy in men with prostate cancer is not associated with COVID‐2019 infection.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 555, doi. 10.1002/pros.24485
- By:
- Publication type:
- Article
Decursin inhibits EGFR‐ERK1/2 signaling axis in advanced human prostate carcinoma cells.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 534, doi. 10.1002/pros.24482
- By:
- Publication type:
- Article
Molecular features and race‐associated outcomes of SPOP‐mutant metastatic castration‐resistant prostate cancer.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 524, doi. 10.1002/pros.24481
- By:
- Publication type:
- Article
Utilization of genetic testing in men with advanced prostate cancer.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 516, doi. 10.1002/pros.24480
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 487, doi. 10.1002/pros.24384
- Publication type:
- Article
Lack of repeatability of radiomic features derived from PET scans: Results from a <sup>18</sup>F‐DCFPyL test–retest cohort.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 547, doi. 10.1002/pros.24483
- By:
- Publication type:
- Article